Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Variable vs Standard Duration Peg-IFN + Ribavirin in Genotype 3 HCV
NCT01121705Phase 3Completed
- Sponsor
- Casa Sollievo della Sofferenza
- Start
- Jan 2007
- Primary completion
- Jun 2009
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C (HCV) (2 arms), sponsored by Casa Sollievo della Sofferenza. Primary endpoint: Sustained Virological Response. Started Jan 2007; status: completed.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01121705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01121705.